Chen et al. [46] suggest that inhibition of myeloid cell COX-2 can potentiate CTL-mediated tumor cytotoxicity and may provide a novel therapeutic approach in breast cancer therapy. This evidence concerns the gene PTGS2 and breast carcinoma.